Theresa Pacheco, MD
Procedural Dermatology · Aurora, CONPI 1003909458
Payments from drug & device makers
Across 51 payments — averaging $1317.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Helsinn Therapeutics (U.S.), Inc.$44K
- Kyowa Kirin Pharmaceutical Development, Inc$21K
- Kyowa Kirin, Inc.$2K
- Medical Device Business Services, Inc.$137
- LEO Pharma Inc.$89
- Sanofi$64
- plus $68 from 4 others
What the payments were for
- Consulting fees$1,9384%
- Speaking & faculty fees$39,23285%
- Travel & lodging$3,9409%
- Food & beverage$7182%
- Education$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Helsinn Therapeutics (U.S.), Inc. | 39 | $43,684 |
| Kyowa Kirin Pharmaceutical Development, Inc | 3 | $21,237 |
| Kyowa Kirin, Inc. | 1 | $1,938 |
| Medical Device Business Services, Inc. | 1 | $137 |
| LEO Pharma Inc. | 1 | $89 |
| Sanofi | 2 | $64 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Abiomed | 1 | $18 |
| Amgen | 1 | $16 |
| Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few procedural dermatology providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ValchlorMechlorethamine Hcl | 20 | $268,211 |
| Humira(Cf) PenAdalimumab | 20 | $213,622 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 15 | $137,645 |
| Dupixent SyringeDupilumab | 28 | $105,323 |
| HumiraAdalimumab | 13 | $90,454 |
| Tacrolimus | 30 | $8,792 |
| Calcipotriene | 41 | $7,935 |
| Fluorouracil | 81 | $5,614 |
| Clindamycin Phosphate | 75 | $3,923 |
| Clobetasol Propionate | 76 | $2,941 |
| Tretinoin | 24 | $2,570 |
| Triamcinolone Acetonide | 125 | $2,363 |
| Imiquimod | 15 | $2,148 |
| ValacyclovirValacyclovir Hcl | 29 | $1,582 |
| Fluocinonide | 46 | $1,497 |
Paid to pharmacies, not to this prescriber.
Other procedural dermatology in Aurora
- Sarolta SzaboHighlands Ranch$7K
- Bradley DraperHighlands Ranch$4K
- Andrew KalajianFort Collins$2K
- Susan SchroederColorado Springs$344
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.